Suppr超能文献

强化血液透析、血压和降压药物的使用。

Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use.

机构信息

American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL.

Wake Forest University Medical Center, Winston-Salem, NC.

出版信息

Am J Kidney Dis. 2016 Nov;68(5S1):S15-S23. doi: 10.1053/j.ajkd.2016.05.026.

Abstract

Hypertension is a cardinal feature of end-stage renal disease (ESRD). Hypertensive nephropathy is the primary cause of ESRD for nearly 30% of patients, and the prevalence of hypertension is >85% in new patients with ESRD. In contemporary hemodialysis (HD) patients, mean predialysis systolic blood pressure (SBP) is nearly 150mmHg, and about 70%, 50%, and 40% use β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, respectively. Predialysis SBP generally exhibits a U-shaped association with mortality risk. Interdialytic ambulatory SBP is more strongly associated with risk. Hypertension is multifactorial; key causes include persistent hypervolemia and elevated peripheral resistance. With 3 HD sessions per week, blood pressure (BP) climbs during the interdialytic interval, in step with interdialytic weight gain, particularly among elderly patients and those with higher dry weight. Elevated peripheral resistance can be attributed to inappropriate activation of the sympathetic nervous system due to higher plasma norepinephrine concentrations. Multiple randomized clinical trials show that intensive HD reduces BP and the need for oral medications indicated for hypertension. In the first 2 months of the Frequent Hemodialysis Network trial, the short daily schedule reduced predialysis SBP by 7.7mmHg, whereas the nocturnal schedule reduced predialysis SBP by 7.3mmHg, both relative to 3 sessions per week. Improvements were sustained after 12 months. Both schedules reduced antihypertensive medication use relative to 3 sessions per week. In FREEDOM (Following Rehabilitation, Economics, and Everyday-Dialysis Outcome Measurements), a prospective cohort study of short daily HD, the mean number of prescribed antihypertensive agents decreased from 1.7 to 1.0 in 1 year, whereas the percentage of patients not prescribed antihypertensive agents increased from 21% to 47%. Nocturnal HD appears to markedly reduce total peripheral resistance and plasma norepinephrine and restore endothelium-dependent vasodilation. In conclusion, intensive HD reduces BP and the need for antihypertensive medications.

摘要

高血压是终末期肾病(ESRD)的主要特征。高血压肾病是近 30%的 ESRD 患者的主要病因,新 ESRD 患者的高血压患病率>85%。在当代血液透析(HD)患者中,平均透析前收缩压(SBP)接近 150mmHg,分别约有 70%、50%和 40%的患者使用β受体阻滞剂、钙通道阻滞剂和肾素-血管紧张素系统抑制剂。透析前 SBP 与死亡率风险呈近似 U 型关系。间歇性动态 SBP 与风险的相关性更强。高血压是多因素的;主要原因包括持续的血容量过多和外周阻力升高。每周进行 3 次 HD 治疗,血压(BP)在透析间期上升,与透析间期体重增加同步,尤其是在老年患者和干体重较高的患者中。外周阻力升高可归因于由于血浆去甲肾上腺素浓度升高而导致的交感神经系统的不适当激活。多项随机临床试验表明,强化 HD 可降低血压和高血压所需的口服药物。在频繁血液透析网络试验的前 2 个月中,短期每日方案使透析前 SBP 降低了 7.7mmHg,而夜间方案使透析前 SBP 降低了 7.3mmHg,与每周 3 次相比。12 个月后仍保持改善。与每周 3 次相比,两种方案均减少了降压药物的使用。在 FREEDOM(以下是康复、经济学和日常透析结果测量的后续)中,一项关于短期每日 HD 的前瞻性队列研究,1 年内处方降压药的平均数量从 1.7 种减少到 1.0 种,而未处方降压药的患者比例从 21%增加到 47%。夜间 HD 似乎可以显著降低总外周阻力和血浆去甲肾上腺素,并恢复内皮依赖性血管舒张。总之,强化 HD 可降低血压和降压药物的需求。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验